mumbai shares sun pharmaceuticals plunged 6 trade today usfda issued import alert karkhadi unit import alert products manufactured karkhadi analyst broking doesnt see 45 per cent revenue hit company due import price target based information management investors wait clarity emerge buying stock said interview et double whammy company usbased competitor pharmaceuticals expects 60 per cent decline doxycycline sales indicated fall doxycycline prices three credit suisse report doxycycline contributes 67 per cent suns eps brokerage expects sun pharma guide per cent fy15 sales pharma usbased subsidiary sun pharma supplies doxycycline benefited due drug shortage bank merrill lynch recently downgraded stock neutral buy citing stiff competition certain key drugs report brokerage said antibiotic doxycycline cancer drug set face incremental competition next 12 stock sun pharma closed rs 57360 503 bse touched high rs 610 low rs 56560 trade today
